Human amniotic epithelial cell therapy- Shanghai iCELL Biotechnology/The Second Affiliated Hospital of Chongqing Medical University

Drug Profile

Human amniotic epithelial cell therapy- Shanghai iCELL Biotechnology/The Second Affiliated Hospital of Chongqing Medical University

Alternative Names: hAECs

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai iCELL Biotechnology
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Genitourinary disorders

Most Recent Events

  • 02 Jan 2018 Zhejiang University in collaboration with Shanghai iCELL Biotechnology plans a phase I trial in Genitourinary disorders (Asherman's Syndrome) (Second-line therapy or greater) in China in March 2017 (NCT03381807) (Trial profile 700291772)
  • 27 Jul 2017 The Second Affiliated Hospital of Chongqing Medical University in collaboration with Shanghai iCELL Biotechnology plans a phase I trial for Genitourinary disorders (Asherman's syndrome) (Second-line therapy) in October 2017 (NCT03223454)
  • 13 Jul 2017 Preclinical trials in Genitourinary disorders in China (Intrauterine) before July 2017 (NCT03223454)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top